Frequently Asked Questions

No increased PTSD risk was observed for patients who filled a new benzodiazepine prescription within 30 days after trauma compared with those who were prescribed one but did not fill it. In this cohort of 15,570 benzodiazepine-naive adults, 12-month cumulative PTSD risk was 5.2% in nonpurchasers, 4.7% in patients who filled within 7 days, and 5.0% in those who filled on days 8730. In the fully adjusted Cox model, neither early purchase (HR 0.98, 95% CI 0.801.20; P=.868) nor late purchase (HR 1.11, 95% CI 0.941.31; P=.218) was associated with a significant increase in PTSD diagnosis.

The study did not find a significant difference in PTSD risk between filling benzodiazepines within 7 days and filling them on days 8730. Direct comparison between early and late purchasers was not significant in the unadjusted model (HR 0.942, 95% CI 0.7871.128; P=.518) or the fully adjusted model (HR 0.885, 95% CI 0.7381.061; P=.186). The authors noted that estimates consistently trended toward lower PTSD risk with earlier redemption, but this pattern was not statistically significant across models.

Yes. Persistent benzodiazepine use was associated with higher subsequent PTSD risk, whereas time-limited use was not. In the 5-group analysis, 12-month cumulative PTSD risk was 9.1% in early-persistent users and 9.9% in late-persistent users, compared with 4.1% in early-discontinuation users, 4.4% in late-discontinuation users, and 5.2% in nonpurchasers. After full adjustment, persistent use remained associated with higher PTSD risk versus nonpurchase: early-persistent HR 1.60 (95% CI 1.142.25; P=.006) and late-persistent HR 2.07 (95% CI 1.602.68; P<.001), while discontinuation groups were not significantly different from nonpurchasers.

A refill request may be a clinically meaningful signal that acute distress has not resolved and that reassessment is needed. The study found higher PTSD incidence among persistent users, but the authors state the observational design cannot determine whether that elevation reflects unresolved underlying symptom severity, more intensive treatment needs, or a medication-related effect. Their clinical implication is to monitor persistence closely and use refill behavior as an opportunity for active reassessment and early identification of patients who may need more comprehensive trauma-focused care.

Among residents near the Gaza border, who represented the highest trauma-exposure subgroup, benzodiazepine purchasers had lower observed PTSD rates than nonpurchasers. Twelve-month cumulative PTSD risk was 53.0% in nonpurchasers versus 31.1% in early purchasers and 35.1% in late purchasers (log-rank P=.026). Unadjusted Cox regression showed HRs of 0.52 (95% CI 0.310.88; P=.015) for early purchasers and 0.62 (95% CI 0.380.98; P=.043) for late purchasers, although the authors caution that this subgroup was small (n=238) and residual confounding remains possible.

The key design feature was comparing patients who all received a new benzodiazepine prescription, then separating those who redeemed it from those who did not. This approach was intended to compare groups with similar physician-assessed acute symptom severity while reducing the usual bias that sicker patients are more likely to receive benzodiazepines. The cohort included 15,570 adults in Clalit Health Services in Israel who were newly prescribed lorazepam, oxazepam, clonazepam, or diazepam within 30 days after October 7, 2023, with no benzodiazepine prescription or purchase in the prior 3 years.

The main findings were consistent in sensitivity analyses limited to incident PTSD and to incident PTSD with a 30-day washout period. In fully adjusted Cox models, benzodiazepine purchase timing remained nonsignificant for the incident-only outcome (early HR 0.91; late HR 1.16; P=.45) and for the incident-plus-30-day-washout outcome (early HR 0.97; late HR 1.18; P=.8). The authors also reported that results were robust after adjustment for concurrent SSRI purchase within 30 days.

The main limitations are that this was an observational study using pharmacy dispensing and routine clinical diagnoses rather than confirmed ingestion or structured PTSD interviews, so causal conclusions cannot be made. Trauma exposure and trauma intensity could not be verified at the individual level, prescription indication was unknown, and residual confounding remained especially possible in the persistence analysis. In addition, exposure timing was measured in days rather than hours, which limits evaluation of very early posttrauma effects, and findings may not generalize outside Israel's universal health care system or this mass-trauma context.

No. The study provides reassurance that short-term, time-limited posttrauma benzodiazepine use was not associated with increased PTSD risk, but it does not endorse routine use. The authors specifically note the well-established risks of dependence and cognitive adverse effects with prolonged exposure and emphasize the central role of evidence-based psychological interventions. Their conclusion is narrower: concern that brief posttrauma benzodiazepine use increases PTSD risk may be less empirically supported than current guidelines assume, while persistent use should prompt closer monitoring and reassessment.